BARCELONA, SPAIN — A new "deescalation" regimen of dual antiplatelet therapy post-ACS—which involves switching from prasugrel (Effient, Lilly/Daiichi-Sankyo) to clopidogrel in certain patients guided ...

December 4, 2009 (Munich, Germany) - Patients undergoing PCI who had an enhanced response to clopidogrel as assessed by a platelet-function test had three times the risk of major bleeding compared ...

A new study, published in the November 17, 2009, issue of the Journal of the American College of Cardiology, adds to a growing body of research seeking to evaluate and understand possible sex ...

Managing drug dosage is critical to the overall success of pharmaceutical intervention, not only in the clinic but also in clinical trials. Inadequate dose management of certain drugs can have fatal ...

Federal drug regulators added a boxed warning to the anti-blood clotting medicine Plavix, alerting physicians and patients that it could be less effective in people who cannot metabolize the pill ...

After surviving a heart attack, patients are often given specific drugs to prevent another one. One of those drugs clopidogrel, sold under the brand name Plavix, may not work as well in patients also ...

The somewhat conflicting results of CURRENT-OASIS 7 have inspired new correspondence in the January 22, 2011, issue of the Lancet that question how best to implement the study’s findings regarding ...

CHICAGO (Reuters) - The popular blood-thinner Plavix prevents heart attacks and strokes in both women and men, but the benefits differ slightly by gender, U.S. researchers said on Monday. They ...

ORLANDO -- The widely used herbal remedy St. John's wort appears to amplify the action of the popular blood-thinning drug clopidogrel, sold as Plavix, a small new clinical study finds. The effect ...

Dear Dr. Roach: I have been on Plavix 75 mg and aspirin 81 mg for years, and I drink green tea daily because of its beneficial qualities. I recently heard that green tea has vitamin K and counteracts ...

AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL, ...